Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Serbian Drugmaker Galenika to Cut Jobs, Wages to Post Profits

Don't Miss Out —
Follow us on:

July 3 (Bloomberg) -- Galenika AD Zemun, a Serbian state-owned drugmaker, needs to cut 800 jobs and lower wages by 20 percent to return to profit, the Finance Ministry said.

The workforce should drop to 1,200 before the state starts talks with banks over rescheduling long-term debt repayments, the ministry said in an e-mail today. The government has asked the Belgrade-based company’s management to prepare cost-cutting plans together with trade unions, it said.

Galenika, whose loss shrank to 5.6 billion dinars ($63.6 million) in 2012 from 13.5 billion dinars a year earlier, is among four companies the government plans to sell to strategic investors. A unit of Canada’s Valeant Pharmaceuticals International Inc. pulled out of a sale tender on June 7.

To contact the reporter on this story: Gordana Filipovic in Belgrade at gfilipovic@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.